Coya Therapeutics grants CEO 293,983 stock options

Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun.

Rhea-AI Filing Summary

Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun. On January 22, 2026, he received a stock option covering 293,983 shares of common stock with an exercise price of $4.73 per share.

These options were granted at a price of $0 for the derivative itself and are held directly. The shares underlying the option vest in monthly installments over 36 months, conditioned on continued service. If there is a change in control of Coya Therapeutics, all unvested shares under this option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

Insider Trade Summary

Grant/Award: 293,983 shares

Grant/Award 1 txn

Insider Swaminathan Arun

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	293,983	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 293,983 contracts (Direct)

Footnotes (1)

1. F1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Coya Therapeutics (COYA) report for its CEO?

Coya Therapeutics reported that Chief Executive Officer Swaminathan Arun was granted a stock option for 293,983 shares of common stock on January 22, 2026.

What is the exercise price of the CEO stock options in this Coya Therapeutics (COYA) Form 4?

The stock option granted to the CEO has an exercise price of $4.73 per share for Coya Therapeutics common stock.

How do the 293,983 CEO stock options at Coya Therapeutics (COYA) vest?

The 293,983 stock options vest in monthly installments over 36 months, subject to the CEO’s continuous service through each vesting date.

What happens to the CEO’s Coya Therapeutics (COYA) stock options upon a change in control?

Upon a change in control of Coya Therapeutics, all shares underlying the CEO’s option will fully vest and the option will become immediately exercisable under the 2021 Equity Incentive Plan.

How many derivative securities does the Coya Therapeutics (COYA) CEO hold after this Form 4 transaction?

Following this transaction, the CEO beneficially owns 293,983 derivative securities in the form of stock options, held directly.

Was there any purchase price paid for the Coya Therapeutics (COYA) stock option grant itself?

The Form 4 indicates a price of $0 for the derivative security itself, with the option exercisable at $4.73 per share for the underlying common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swaminathan Arun

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.73	01/22/2026		A		293,983		(1)	01/22/2036	Common Stock, par value $0.0001 per share	293,983	$0	293,983	D

Explanation of Responses:

1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

	/s/ David Snyder, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.